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STATE OF MAINE
KENNEBEC, SS.

SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-20- l b
)
)
)
)
)
)
)
)
)
)

STATE OF MAINE,
Plaintiff
v.
C. R. BARD, INC.,
Defendant

5

CONSENT JUDGMENT

Plaintiff, the State of Maine has filed a Complaint for a permanent injunction and other
relief in this matter, pursuant to 5 M.R.S.A. § 209 of Maine’s Unfair Trade Practices Act (the
“UTPA,” 5 M.R.S.A. §§ 205-A through 214), alleging that Defendant C. R. Bard, Inc. (“BARD”
or “Defendant”) committed violations of the aforementioned Act. Plaintiff, by its counsel, and
BARD, by its counsel, have agreed to the entry of this Consent Judgment (the “Judgment”) by the
Court without trial or adjudication of any issue of fact or law, and without finding or admission of
wrongdoing or liability of any kind.
IT IS HEREBY ORDERED THAT:
1.

FINDINGS

1.1.

This Court has jurisdiction over the subject matter of this lawsuit and over all

1.2.

The terms of this Judgment shall be governed by the laws of the State of Maine.

1.3.

Entry of this Judgment is in the public interest and reflects a negotiated agreement

Parties.

among the Parties.

1.4.

The Parties have agreed to resolve the issues resulting from the Covered Conduct

by entering into this Judgment.1
1.5.

BARD is willing to enter into this Judgment regarding the Covered Conduct in

order to resolve the Attorneys General’s concerns under the State Consumer Protection Laws as
to the matters addressed in this Judgment and thereby avoid significant expense, inconvenience,
and uncertainty.
1.6.

BARD is entering into this Judgment solely for the purpose of settlement, and

nothing contained herein may be taken as, or construed to be, an admission or concession of any
violation of law, rule, or regulation, or of any other matter of fact or law, or of any liability or
wrongdoing, all of which BARD expressly denies. BARD does not admit any violation of the
State Consumer Protection Laws set forth in footnote 4, and does not admit any wrongdoing that
was, or could have been, alleged by any Attorney General before the date of the Judgment under
those laws. No part of this Judgment, including its statements and commitments, shall constitute
evidence of any liability, fault, or wrongdoing by BARD.
1.7.

This Judgment shall not be construed or used as a waiver or limitation of any

defense otherwise available to BARD in any other action, or of BARD’s right to defend itself from,
or make any arguments in, any other private individual, regulatory, governmental, or class claims
or suits relating to the subject matter or terms of this Judgment. This Judgment is made without
trial or adjudication of any issue of fact or law or finding of liability of any kind. Notwithstanding
the foregoing, a State may file an action to enforce the terms of this Judgment.

IrThis Consent Judgment is entered into pursuant to and subject to the State Consumer Protection laws cited
in footnote 4.
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1.8.

No part of this Judgment shall create a private cause of action or confer any right

to any third party for violation of any federal or state statute except that a State may file an action
to enforce the terms of this Judgment. It is the intent of the Parties that this Judgment shall not be
binding or admissible in any other matter, including, but not limited to, any investigation or
litigation, other than in connection with the enforcement of this Judgment.
1.9.

This Judgment (or any portion thereof) shall in no way be construed to prohibit

BARD from making representations with respect to any BARD products in Labeling that are
required under Federal law, regulations, or policies or guidance having the force of law, including
in Food and Drug Administration (“FDA”) approved Labeling.
1.10.

Nothing in this Judgment shall require BARD to :
(a)

Take any action that is prohibited by the Food, Drug and Cosmetic Act, 21
U.S.C. § 301 etseq. (“FDCA”) or any regulation promulgated thereunder,
or by the FDA; or

(b)

Fail to take any specific action that is expressly permitted or is required by
the FDCA or any regulation promulgated thereunder.
2.

DEFINITIONS

The following definitions shall be used in construing the Judgment:
2.1.

“Covered Conduct” means BARD’s marketing and promotional practices, and

dissemination of information to Health Care Providers and consumers, regarding Urogynecologic
Surgical Mesh products including, but not limited to, the dissemination of Marketing Materials,
disclosure of Significant or Inherent Complications in Instructions for Use (“IFUs”), Sponsorship
of any programs, training any sales professionals, the publication of any clinical or pre-clinical
data, or the reporting of MDRs or adverse events, through the Effective Date of the Judgment.
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2.2.

“Effective Date” means the date on which a copy of the Judgment, duly executed

by BARD and by the Signatory Attorney General, is approved by, and becomes a Judgment of the
Court.
2.3.

“Health Care Provider” or “HCP” means any physician or other health care

practitioner who is licensed to provide health care services.
2.4.

“BARD” means C. R. Bard, Inc. and Becton, Dickinson and Company and all of

their officers, directors, employees, representatives, agents, affiliates, parents, subsidiaries,
operating companies, assigns and successors.
2.5.

“Labeling” means “all labels and other written, printed, or graphic matter (1) upon

any article or any of its containers or wrappers, or (2) accompanying such article,” as defined under
Section 201 (m) of the FDCA.
2.6.

“Marketing Materials” means any written, electronic, or verbal material or

statements either publicly disseminated (including videos, websites it hosts or controls, or any
other form of media) or made for the purpose of public dissemination in the United States, in the
course of marketing, promoting, or informing HCPs, consumers, or patients about Urogynecologic
Surgical Mesh including, but not limited to, HCP training materials and training materials for sales
representatives made for the purpose of public dissemination and delivery to HCPs.
2.7.

“Multistate Executive Committee” means the Attorneys General and their staffs

representing California, Florida, Indiana, Maryland, Ohio, South Carolina, Texas, and
Washington.
2.8.

“Multistate Working Group” means the Attorneys General and their staffs

representing Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware,
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District of Columbia, Florida, Georgia, Hawaii,2 Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky,
Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri,
Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North
Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina,
South Dakota, Tennessee, Texas, Utah,3 Vermont, Virginia, Washington, and Wisconsin.
2.9.

“Parties” means BARD as defined in Section 2.4 and the Signatory Attorney

General.
2.10.

“Post-effective Date Urogynecologic Surgical Mesh” means Urogynecologic

Surgical Mesh that enters the market in the United States after the Effective Date, and that is not
identical or substantially equivalent to Urogynecologic Surgical Mesh that was on the market in
the United States prior to the Effective Date.
2.11.

“Significant Complications” means all complications of Urogynecologic Surgical

Mesh, including complications discovered subsequent to the Effective Date, which constitute
clinically significant risks material to an HCP’s decision to implant Urogynecologic Surgical
Mesh.
2.12.

“Inherent Mesh Complications” means Significant Complications that may not be

eliminated with surgical technique and are associated with the use of Urogynecologic Surgical
Mesh. Disclosure of such risks shall include an adequate description of the chronicity, acuteness,

2 Hawaii is represented on this matter by its Office of Consumer Protection, an agency which is not part of
the state Attorney General*s Office, but which is statutorily authorized to undertake consumer protection functions,
including legal representation o f the State o f Hawaii. For simplicity, the entire* group will be referred to as the
“Attorneys General,” and such designation, as it includes Hawaii, refers to the Executive Director of the State of
Hawaii Office of Consumer Protection.
3With regard to Utah, the Utah Division of Consumer Protection is charged with administering and enforcing
the Consumer Sales Practices Act, the statute relevant to this Judgment. References to the “States,” “Parties,” or
“Attorneys General,” with respect to Utah, refers to the Utah Division o f Consumer Protection.
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and permanence of the risks. A non-verbatim description of these risks shall include, but are not
limited to, risks of:
•

Exposure of mesh material into the vagina, which can be associated with pain
during intercourse for the woman and/or her partner;

•

Pain caused by exposure may be severe and may result in permanent sexual
dysfunction;

•

Erosion;

•

Implantation of Urogynecologic Surgical Mesh through the vagina may cause
bacterial contamination;

•

Infection;

•

Voiding dysfunction, including de novo urge incontinence;

•

Foreign body reaction;

•

Inflammation;

•

Scar plating around mesh;

•

Clinical consequences of mesh contracture;

•

Acute and/or chronic pain;

•

Pelvic pain, which in some patients may not resolve;

•

Pain with intercourse, which in some patients may not resolve;

•

Excessive contraction or shrinkage of the tissue surrounding the mesh, vaginal
scarring, tightening and/or shortening may occur.

Such description shall also note that the occurrence of one or more of these complications may
require treatment or surgical intervention:
i.

In some instances, the complication may persist as a permanent
condition after the surgical intervention or other treatment;
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ii.

Removal of mesh or correction of mesh-related complications may
involve multiple surgeries; and

iii.

Complete removal of mesh may not be possible and additional
surgeries may not always fully correct the complications

However, for Post-Effective Date Urogynecologic Surgical Mesh, a non-verbatim description of
these risks may include, but are not limited to, the risks listed in the bullet points above, depending
upon the available Valid Scientific Evidence.
2.13.

“Signatory Attorney General” means the Attorney General of Maine, or his

authorized designee, who has agreed to this Judgment.
2.14.

“Sponsor” or “Sponsorship” means to pay for in whole or in part, to provide

financial support or subsidization, or to provide goods or materials of value in support, but does
not include de minimis support.
2.15.

“State Consumer Protection Laws” means the consumer protection laws cited in

footnote 4 under which the Attorneys General have conducted the investigation.4

4ALABAMA - Alabama Deceptive Trade Practices Act § 8-19-1 et seq. (2002); ALASKA - Alaska Unfair
Trade Practices and Consumer Protection Act AS 45.50.471 - 45.50.561; ARIZONA - Consumer Fraud Act, A.R.S.
§44-1521 et seq.; ARKANSAS - Arkansas Deceptive Trade Practices Act, Ark. Code Ann. § 4-88-101, et seq.;
CALIFORNIA -B us. & Prof Code §§ 17200 et seq. and 17500 et seq.; COLORADO - Colorado Consumer Protection
Act, Colo. Rev. Stat. § 6-1-101 et seq.; CONNECTICUT - Connecticut Unfair Trade Practices Act, Conn. Gen Stat.
§§ 42-110a through 42-1 lOq; DELAWARE - Delaware Consumer Fraud Act, Del. CODE ANN. tit. 6, §§ 2511 to
2527; DISTRICT OF COLUMBIA, District of Columbia Consumer Protection Procedures Act, D.C, Code §§ 283901 et seq.; FLORIDA - Florida Deceptive and Unfair Trade Practices Act, Part n , Chapter 501, Florida Statutes,
501.201 et. seq.; GEORGIA - Fair Business Practices Act, O.C.G.A. Sections 10-1-390 et seq.; HAWAII - Uniform
Deceptive Trade Practice Act, Haw. Rev. Stat. Chpt. 481A and Haw. Rev. Stat. Chpt. 480; IDAHO - Idaho Consumer
Protection Act, Idaho Code § 48-601 et seq.; ILLINOIS - Consumer Fraud and Deceptive Business Practices Act, 815
ILCS 505/2 et seq,; INDIANA - Deceptive Consumer Sales Act, Ind. Code §§ 24-5-0.5-0.1 to 24-5-0.5-12; IOWA Iowa Consumer Fraud Act, Iowa Code Section 714.16; KANSAS - Kansas Consumer Protection Act, K.S.A. 50-623
et seq.; KENTUCKY - Kentucky Consumer Protection Act, KRS Ch. 367.110, et seq.; LOUISIANA - Unfair TradePractices and Consumer Protection Law, LSA-R.S. 51:1401, et seq.; MAINE - Unfair Trade Practices Act, 5 M.R.S.A.
§§ 205-A through 214; MARYLAND - Maryland Consumer Protection Act, Md. Code Ann., Com. Law §§ 13-101 et
seq.; MASSACHUSETTS - Mass. Gen. Laws c. 93A, §§ 2 and 4; MICHIGAN - Michigan Consumer Protection Act,
MCL § 445.901 et seq.; MINNESOTA - Minn. Stat. §§325D.44, 325F.69; MISSISSIPPI - Mississippi Consumer
Protection Act, Miss. Code Ann.§ 75-24-1, et seq.; MISSOURI - Missouri Merchandising Practices Act, Mo. Rev.
Stat. §§ 407.010 et seq.; MONTANA - Montana Consumer Protection Act §§ 30-14-101 et seq.; NEBRASKA Consumer Protection Act, Neb. Rev, Stat. §§ 59-1601 et seq. and Uniform Deceptive Trade Practices Act, Neb. Rev.
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2.16.

“Urogynecologic Surgical Mesh” means any medical device cleared or approved

by the FDA (as the term “device” is defined in 21 U.S.C. § 321(h)) that contains synthetic, multi1

strand, knitted, or woven mesh and that is indicated to be used for implantation in the pelvic floor
to treat stress urinary incontinence (“SUI”) and/or pelvic organ prolapse (“POP”) sold or marketed
in the United States.
2.17.

“Valid Scientific Evidence” means evidence from well-controlled investigations,

partially controlled studies, studies and objective trials without matched controls, welldocumented case histories conducted by qualified experts, or reports of significant human
experience with a marketed device, from which it can fairly and responsibly be concluded by
qualified experts that there is reasonable assurance to substantiate that a representation is true.
2.18.

Any reference to a written document shall mean a physical paper copy of the

document, electronic version of the document, or electronic access to such document.

Stat. §§ 87-301 et seq.; NEVADA -D eceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.; NEW
HAMPSHIRE - NH RSA §358-A et seq; NEW JERSEY - New Jersey Consumer Fraud Act, NJSA 56:8-1 et seq.;
NEW MEXICO -N M S A 1978, § 57-12-1 et seq.; NEW YORK - General Business Law Art. 22-A, §§ 349-50, and
Executive Law § 63(12); NORTH CAROLINA -N o rth Carolina Unfair and Deceptive Trade Practices Act, N.C.G.S.
75-1.1, et seq.; NORTH DAKOTA - Unlawful Sales or Advertising Practices, N.D. Cent. Code § 51-15-02 et seq.;
OHIO - Ohio Consumer Sales Practices Act, R.C. 1345.01, et seq.; OKLAHOMA - Oklahoma Consumer Protection
Act 15 O.S. §§ 751 et seq.; OREGON - Oregon Unlawful Trade Practices Act, Or, Rev. Stat. § 646.605 et seq.;
PENNSYLVANIA - Pennsylvania Unfair Trade Practices and Consumer Protection Law, 73 P.S. 201-1 et seq.;
RHODE ISLAND - Deceptive Trade Practices Act, Rhode Island Gen. Laws §6-13.1-1, et seq.; SOUTH CAROLINA
—South Carolina Unfair Trade Practices Act, S.C. Code Ann. § 39-5-10 et seq.; SOUTH DAKOTA —South Dakota
Deceptive Trade Practices and Consumer Protection, SDCL ch, 37-24; TENNESSEE — Tennessee Consumer
Protection Act, Tenn. Code Ann. 47-18-101 et seq.; TEX A S-Texas Deceptive Trade Practices-Consumer Protection
Act, Tex. Bus. And Com. Code 17.41, et seq.; UTAH - Consumer Sales Practices Act, Utah Code Ann. §§13-11-1 et
seq.; VERMONT - Vermont Consumer Protection Act, 9 V.S.A. § 2451, et seq.; VIRGINIA-Virginia Consumer
Protection Act, Va Code Ann. §59.1-196 et seq.; WASHINGTON - Unfair Business Practices/Consumer Protection
Act, RCW §§ 19.86 et seq.; WISCONSIN - Wis. Stat. § 100.18 (Fraudulent Representations).
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3.

A.

COMPLIANCE PROVISIONS

Exit from Urogynecologic Surgical Mesh Business
3.1.

BARD states that it ceased the marketing, promotion, sale, and distribution of

Urogynecologic Surgical Mesh in the United States and the manufacturing of Urogynecologic
Surgical Mesh for sale in the United States by December 30, 2016.
3.2.

In the event that BARD engages in any conduct involving the manufacture,

promotion, marketing, sale, or distribution of Urogynecologic Surgical Mesh, either directly or
indirectly through any third parties, in the United States, it shall be bound by the following
provisions contained in Sections 3.4 through 3.27 of this Judgment for ten (10) years from the date
of first sale of an Urogynecologic Surgical Mesh product in the United States or for twenty (20)
years from the Effective Date of this Judgment, whichever is less. Section 3.3 is not time restricted.
Nothing in this Judgment shall be construed to require BARD, for any Urogynecologic Surgical
Mesh product approved through the FDA Premarket Approval process, to utilize product labeling
different from that which is approved by the FDA.
B.

Marketing, Information, and Training
3.3.

In promoting Urogynecologic Surgical Mesh, BARD shall not violate 5 M.R.S.A.

§ 207 of the UTPA.
3.4.

BARD shall not, in any Marketing Materials, make any claim comparing safety or

efficacy clinical outcomes with the use of Urogynecologic Surgical Mesh to any non-mesh
procedure safety or efficacy clinical outcomes, unless any such representation is supported by
Valid Scientific Evidence. BARD, however, may make comparisons in any Marketing Materials
not involving safety or efficacy clinical outcomes, if not false, misleading, or deceptive.
3.5.

BARD shall not, in any Marketing Materials, misrepresent the safety or efficacy of

its Urogynecologic Surgical Mesh by omitting Significant Complications or Inherent Mesh
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Complications, as appropriate given the length, context, medium, and placement of the Marketing
Material, and in all instances where the Marketing Material purports to address the subject of
complications.
3.6.

In any Marketing Material that is intended to reach patients or consumers other

than, or in addition to, HCPs, BARD shall also include descriptions of Significant Complications
and Inherent Mesh Complications in terms reasonably understandable to a patient.
3.7.

BARD shall not, in any Marketing Materials, misrepresent the extent to which

Inherent Mesh Complications are risks or complications common to all pelvic floor or other
surgeries.
3.8.

BARD shall not, in any Marketing Materials, represent or imply that Significant

Complications or Inherent Mesh Complications can be eliminated with surgical experience or
technique alone. However, for Post-Effective Date Urogynecologic Surgical Mesh, BARD may,
in any Marketing Materials, represent or imply that Significant Complications can be eliminated
with surgical experience or technique alone, if such statement is supported by Valid Scientific
Evidence.
3.9.

BARD shall not represent or imply that such Urogynecologic Surgical Mesh does

not cause a foreign body reaction, including any chronic foreign body reaction, after the
Urogynecologic Surgical Mesh is implanted inside the body. However, for Post-Effective Date
Urogynecologic Surgical Mesh, BARD may represent or imply that such Urogynecologic Surgical
Mesh does not cause a foreign body reaction, including any chronic foreign body reaction, after
the Urogynecologic Surgical Mesh is implanted inside the body, if such statement is supported by
Valid Scientific Evidence.
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3.10.

BARD shall not, in any Marketing Materials, represent or imply that such

Urogynecologic Surgical Mesh is “soft” or that it has “multidirectional elasticity” within the body
after implantation, or use any other phrases having an equivalent meaning. However, for PostEffective Date Urogynecologic Surgical Mesh, BARD may, in any Marketing Materials, represent
or imply that such Urogynecologic Surgical Mesh is “soft” or that it has “multidirectional
elasticity” within the body after implantation or use any other phrases having an equivalent
meaning, if such statement is supported by Valid Scientific Evidence. Nothing shall prevent
BARD from making claims to HCPs about the softness and elasticity of Urogynecologic Surgical
Mesh prior to implantation inside the body, provided the claims do not suggest these properties
are retained in the body.
3.11.

BARD shall not, in any Marketing Materials, represent or imply that such

Urogynecologic Surgical Mesh, including its collagen Urogynecologic Surgical Mesh, helps the
body more readily accept a foreign body implant, or reduces the risk of foreign body reaction,
erosion, infection, or any other Urogynecologic Surgical Mesh complications, including any
Significant Complications or Inherent Complications.

However, for Post-Effective Date

Urogynecologic Surgical Mesh, BARD may, in any Marketing Materials, represent or imply that
such Urogynecologic Surgical Mesh, including its collagen Urogynecologic Surgical Mesh, helps
the body more readily accept a foreign body implant, or reduces the risk of foreign body reaction,
erosion, infection, or any other Urogynecologic Surgical Mesh complications, including any
Significant Complications or Inherent Complications, if such statement is supported by Valid
Scientific Evidence.
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3.12.

BARD shall not, in any Marketing Materials, misrepresent the FDA’s approval or

clearance status of its Urogynecologic Surgical Mesh devices, or the extent to which any of its
Urogynecologic Surgical Mesh products have been studied or clinically proven.
3.13.

BARD shall not, in any Marketing Materials, misrepresent the complexity of

Urogynecologic Surgical Mesh implantation procedures or the level of surgical skill and/or
experience necessary to perform these procedures safely. Moreover, BARD employees shall not
encourage an HCP to perform Urogynecologic Surgical Mesh implants without receiving adequate
information and training on how to implant its Urogynecologic Surgical Mesh.
3.14.

In any training in which BARD provides risk information, either directly or through

third parties, to any HCP, BARD shall disclose all Significant Complications and Inherent Mesh
Complications of its Urogynecologic Surgical Mesh.
3.15.

BARD shall ensure, in the marketing and promotion of any Urogynecologic

Surgical Mesh product, that its Marketing Materials and other communications do not misrepresent
FDA updates or communications regarding Urogynecologic Surgical Mesh.
C.

Disclosures to Health Care Providers
3.16.

To the extent not prohibited by federal law, BARD shall ensure that all IFUs for its

Urogynecologic Surgical Mesh products cleared through the 510(k) process include a list of all
known Significant Complications and Inherent Mesh Complications.
3.17.

BARD shall evaluate emerging risk information on an ongoing basis and, consistent

with such risk information, shall update the warnings and precautions section of IFUs and all
Marketing Material to include Significant Complications associated with its Urogynecologic
Surgical Mesh products as soon as practicable. If Bard obtains, receives, or is aware of any new
risk information that necessitates a more immediate disclosure for public health and safety
purposes, Bard shall notify HCPs of this information through other means, such as notices or “dear
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doctor letters/’ as appropriate given the nature of the new information and unless otherwise
directed by the FDA.
D.

Studies, Clinical Data, and Sponsorship
3.18.

BARD shall, when citing to any clinical study, clinical data, or preclinical data,

present a fair and balanced view of available scientific literature with respect to the safety, efficacy,
risks and complications of Urogynecologic Surgical Mesh.
3.19.

BARD shall not misrepresent, when citing to any clinical study, clinical data, or

preclinical data regarding Urogynecologic Surgical Mesh in its Marketing Materials, the results,
scope, or clinical significance of any particular clinical study, clinical data, or preclinical data,
including by implying a more favorable result than supported by the study or data.
3.20.

BARD shall disclose, when submitting a clinical study, clinical data, or preclinical

data regarding Urogynecologic Surgical Mesh for publication, BARD’s role as a Sponsor and any
author’s potential conflict of interest consistent with the disclosure requirements for the
International Committee of Medical Journal Editors (“ICMJE”) or, if different, the disclosure
policies of the relevant publication.
3.21.

BARD shall not cite to any clinical study, clinical data, or preclinical data regarding

Urogynecologic Surgical Mesh for which BARD has not complied with the requirements of
Section III(D) of this Judgment.
3.22.

BARD shall not cite to any clinical study, clinical data, or preclinical data regarding

Urogynecologic Surgical Mesh for which any author/consultant, to the extent BARD knows, has
not complied with the applicable publication’s conflict disclosure requirements, unless BARD
discloses the conflict in a clear and conspicuous manner when citing to such study or data.
3.23.

In all contracts for consulting services regarding Urogynecologic Surgical Mesh

between BARD and any HCP or other author/consultant, BARD shall include a Sponsorship
-13-

I.

disclosure provision under which the HOP or other author/consultant agrees that he or she shall
disclose, in terms likely to be read and understood by the audience, in any public presentation or
submission for publication BARD’s sponsorship of the contracted-for activities. BARD shall also
include a disclosure clause under which the HOP or other author/consultant acknowledges that
BARD may publicly report the fact that BARD made value transfers to him or her. To the extent
within its control, BARD shall ensure that any HCP or author/consultant who submits for
publication a clinical study, clinical data, or pre-clinical data that BARD has Sponsored, authored,
or edited, in whole or in part, shall comply with the publication’s conflict disclosure requirements.
3.24.

In accordance with applicable law, BARD shall register BARD-sponsored clinical

studies regarding its Urogynecologic Surgical Mesh with ClinicalTrials.gov. BARD shall also
retain any design history files and clinical records, including, but not limited to, clinical data,
relating to its post-December 30, 2016 Urogynecologic Surgical Mesh devices and any
Urogynecologic Surgical Mesh devices that existed prior to December 30, 2016 (or substantially
equivalent to such devices) over which it has or should have possession, custody or control for 15
years past the last sale date of the Urogynecologic Surgical Mesh devices to which those files and
records apply, unless a longer period is required by applicable law. BARD shall retain any nonclinical data relating to its post-December 30, 2016 Urogynecologic Surgical Mesh devices and
any Urogynecologic Surgical Mesh devices that existed prior to December 30, 2016 (or
substantially equivalent to such devices) over which it has, or should have, possession, custody or
control until December 30, 2031, if not introduced prior to that date. If introduced prior to
December 30, 2031, then BARD shall retain non-clinical data for 15 years past the last sale date,
unless a longer period is required by applicable law.
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E.

BARD Internal Policies and Training
3.25.

BARD shall ensure that its independent contractors, agents, and employees who

sell, market, or promote Urogynecologic Surgical Mesh or otherwise train, provide information to,
or communicate with, HCPs regarding Urogynecologic Surgical Mesh, are adequately informed
and trained regarding their obligations to report all patient complaints and/or adverse events to
BARD.
3.26.

BARD shall ensure that its company practices regarding the reporting of patient

complaints relating to Urogynecologic Surgical Mesh as MDR reportable adverse events are
consistent with FDA requirements.
F.

Monitoring and Compliance
3.27.

BARD shall be responsible for ensuring monitoring and compliance with the

provisions of this Judgment.
4.
4.1.

PAYMENT

BARD shall pay a total amount of $60 million as follows: 1) the initial payment of

$15 million shall be paid by the later of October 30, 2020 or 30 days after the Effective Date; 2)
the second payment of $ 15 million shall be paid by April 1, 2021; and 3) the final payment of $3 0
million shall be paid by October 30, 2021. These payments will be divided and paid by BARD to
each Signatory Attorney General of the Multistate Working Group in amounts to be designated by
and in the sole discretion of the Multistate Executive Committee.5 Said payments shall be used by
the States as attorneys’ fees and other costs of investigation and litigation, or to be placed in, or
applied to, the consumer protection enforcement, including future consumer protection
enforcement, consumer education, litigation or local consumer aid fund or revolving fund, used to

5 The total payment, over three installments, to the State of Maine shall be $659,787.
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1

defray the costs of the inquiry leading hereto, or for any lawful purpose, at the sole discretion of
each Signatory Attorney General. The Parties acknowledge that the payments described herein
are not a fine, penalty, or payment in lieu thereof.
5.
5.1.

ENFORCEMENT

For the purposes of resolving disputes with respect to compliance with this

Judgment, should any of the Signatory Attorneys General have a reasonable basis to believe that
BARD has engaged in a practice that violates a provision of this Judgment subsequent to the
Effective Date, then such Attorney General shall notify BARD in writing of the specific objection,
identify with particularity the provision of this Judgment that the practice appears to violate, and
give BARD thirty (30) days to respond to the notification; provided, however, that a Signatory
Attorney General may take any action if the Signatory Attorney General believes that, because of
the specific practice, a threat to the health or safety of the public requires immediate action.
5.2.

Upon receipt of written notice, BARD shall provide a good-faith written response

to the Attorney General notification, containing either a statement explaining why BARD believes
it is in compliance with the Judgment, or a detailed explanation of how the alleged violation
occurred and a statement explaining how BARD intends to remedy the alleged breach. Nothing
in this section shall be interpreted to limit the Maine Attorney General's authority to issue a Civil
Investigative Demand (“CID”) or investigative subpoena authority, to the extent such authority
exists under applicable law, and BARD reserves all of its rights in responding to a CID or
investigative subpoena issued pursuant to such authority.
5.3.

The Attorney General may agree, in writing, to provide BARD with additional time

beyond the thirty (30) days to respond to a notice provided under Section 5.1 above.
5.4.

Upon giving BARD thirty (30) days to respond to the notification described above,

the Signatory Attorney General shall also be permitted reasonable access to inspect and copy
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relevant, non-privileged, non-work product records and documents in the possession, custody, or
control of BARD that relate to BARD’s compliance with each provision of this Judgment pursuant
to the Maine Attorney General’s authority to issue a CID or investigative subpoena.. If the
Signatory Attorney General makes or requests copies of any documents during the course of that
inspection, the Signatory Attorney General shall provide a list of those documents to BARD.
5.5.

The State may assert any claim that BARD has violated this Judgment in a separate

civil action to enforce compliance with this Judgment, or may seek any other relief afforded by
law for violations of the Judgment, but only after providing BARD an opportunity to respond to
the notification described in Section 5.1 above; provided, however, that a Signatory Attorney
General may take any action if the Signatory Attorney General believes that, because of the
specific practice, a threat to the health or safety of the public requires immediate action.
6.
6.1.

RELEASE

Released Claims. By its execution of this Judgment, the State of Maine releases

and forever discharges BARD and its past and present officers, directors, employees,
representatives, agents, affiliates, parents, subsidiaries, operating companies, predecessors, assigns
and successors (collectively, the “Releasees”) from the following: all civil causes of action,
claims, damages, restitution, disgorgement, fines, costs, attorney’s fees, or penalties that the Maine
Attorney General has asserted or could have asserted against the Releasees under the State
Consumer Protection Laws, or any amendments thereto, or by common law claims concerning
deceptive or fraudulent trade practices, that the Signatory Attorney General has the authority to
release resulting from the Covered Conduct up to and including the Effective Date. For purposes
of this Section 6.1, Releasees do not include Covidien Ltd. or Medtronic PLC, or their past and
present officers, directors, employees, representatives, agents, affiliates, parents, subsidiaries,
operating companies, predecessors, assigns and successors.
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6.2.

Claims Not Covered. Notwithstanding any term of this Judgment, specifically

reserved and excluded from the release in Section 6.1 as to any entity or person, including
Releasees, are any and all of the following claims:
(a)

Any criminal liability that any person or entity, including Releasees, has
or may have to the State of Maine;

(b)

Any civil or administrative liability that any person and/or entity,
including Releasees, has or may have to the State of Maine not expressly
covered by the release in Section 6.1, including, but not limited to, any
and all of the following claims:
i.

State or federal antitrust violations;

ii.

Claims involving “best price,” “average wholesale price,”
“wholesale acquisition cost,” or any reporting practices;

iii.

Medicaid claims, including, but not limited to, federal Medicaid
drug rebate statute violations, Medicaid fraud or abuse (whether
common law, statutory or otherwise), and/or kickback violations
related to any state’s Medicaid program;

(c)

iv.

State false claims violations; and

v.

Claims to enforce the terms and conditions of this Judgment.

Actions of, or on behalf of, state program payors of the State of Maine
arising from the purchase of Uro gynecologic Surgical Mesh.

(d)

Any claims individual consumers have or may have under above-cited
State Consumer Protection Laws against any person or entity, including
the Releasees.
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6.3.

Nothing contained in this Judgment shall relieve BARD of the obligations it

maintains under any other Judgment, Order or agreement relating to any BARD product.
7.
7.1.

ADDITIONAL PROVISIONS

Nothing in this Judgment shall be construed to authorize or require any action by

BARD in violation of applicable federal, state, or other laws.
7.2.

Modification. The Judgment/Order may be modified by a stipulation of the Parties

as approved by the Court, or by court proceedings resulting in a modified judgment of the Court.
7.3.

BARD shall not cause or encourage third parties, nor knowingly permit third parties

acting on its behalf, to engage in practices from which BARD is prohibited by this
Judgment/Order.
7.4.

The acceptance of this Judgment by the State of Maine shall not be deemed

approval by the State of Maine of any of BARD’s advertising or business practices. Further,
neither BARD nor anyone acting on its behalf shall state or imply, or cause to be stated or implied,
that the State of Maine or any other governmental unit of has approved, sanctioned or authorized
any practice, act, advertisement, or conduct of BARD.
7.5.

Any failure by any party to this Judgment to insist upon the strict performance by

any other party of any of the provisions of this Judgment shall not be deemed a waiver of any of
the provisions of this Judgment, and such party, notwithstanding such failure, shall have the right
thereafter to insist upon the specific performance of any and all of the provisions of this Judgment.
7.6.

Entire Agreement: This Judgment represents the iull and complete terms of the

settlement entered into by the Parties hereto. In any action undertaken by the Parties, no prior
versions of this Judgment and no prior versions of any of its terms that were not entered by the
Court in this Judgment, may be introduced for any purpose whatsoever.
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7.7.

Jurisdiction: This Court retains jurisdiction of this Judgment and the Parties hereto

for the purpose of enforcing and modifying this Judgment and for the purpose of granting such
additional relief as may be necessary and appropriate.
7.8.

Counterparts: This Judgment may be executed in counterparts, and a facsimile or

,pdf signature shall be deemed to be, and shall have the same force and effect as, an original
signature.
7.9.

Notice: All Notices under this Judgment shall be provided to the following via

email and Overnight Mail:
Defendant:
Greg A. Dadika
Senior Vice President, Chief Legal Counsel
Becton Dickinson and Company
Greg .Dadika@bd. com
Copy to BARD’s attorneys at
Troutman Pepper via electronic mail sent to:
Barry H. Boise (barry.boise@troutman.com)
Signatory Attorney General:
Linda J. Conti
Chief, Consumer Protection Division
Office of the Maine Attorney General
Linda. conti@maine.gov
7.10.

To the extent that any provision of this Judgment obligates BARD to change any

policy(ies) or procedure(s) and to the extent not already accomplished, BARD shall implement the
policy(ies) or procedure(s) as soon as reasonably practicable, but no later than 120 days after the
Effective Date of this Judgment.
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Dated:

Dated:

^ f 2oZ.

MAINE ATTORNEY GENERAL
AARON M. FREY

Linda J. Coq|i, Maine Bar No. 36j
Linda. conti@maine. gov
Carolyn A. Silsby, Maine Bar No. 3030
Carolvn.silsbv@maine.gov
Assistant Attorneys General
Office of the Maine Attorney General
6 State House Station
Augusta, ME 04333-0006
(207) 626-8800
ATTORNEYS FOR PLAINTIFF
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Approved:
For Defendant C.R. Bard, Inc.

Greg A. Dadika
Senior Vice President, Chief Legal Counsel
Becton Dickinson and Company
Greg.Dadika@bd.com

-
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Date

Dated:

r-

Andrew P. Ketterer, Maine Bar No. 4671
andrew@kettererlaw. com
KETTERER & KETTERER
60 Main St.
PO Box 417
Norridgewock, ME 04957
(207) 634-2800
(207) 634-2801 fax
ATTORNEYS FOR DEFENDANT
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